BigHat obtains access to Synaffix's site-specific ADC technology platform, and plans to combine Synaffix technology with its advanced ML antibody design platform to develop a new ADC pipeline

Similarly, AbbVie is collaborating with BigHat Biosciences to develop next-generation antibody therapeutics using the Milliner platform, focusing on oncology and neuroscience.

SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson Johnson company. This strategic collaboration combines the drug discovery, clinical development and data science expertise from Johnson Johnson with BigHat’s Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson Johnson Innovation. BigHat’s antibody design platform, Milliner™, integrates a synthetic biology-based high-speed wet lab with state-of-the-art machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins to tackle conditions ranging from chronic illness to life-threatening disease, while also massively speeding up candidate discovery and validation. "We’re delighted to be collaborating with Johnson Johnson to utilize BigHat’s Milliner™ platform to accelerate protein design," stated Mark DePristo, CEO and Co-founder of BigHat